AbbVie announces phase III induction study, U-ACHIEVE, of upadacitinib in moderate to severe ulcerative colitis meets primary endpoint of clinical remission at week 8

Abbvie reports that 26% of patients receiving upadacitinib, an oral, once-daily, selective and reversible JAK inhibitor, achieved clinical remission compared to 5% in the placebo group. U-ACHIEVE is the first of two Phase III induction studies.

Source:

Biospace Inc.